OmniaBio

About OmniaBio

OmniaBio is a contract development and manufacturing organization specializing in the production of gene-modified cell therapies and lentiviral vectors, facilitating the transition from preclinical development to commercial-scale manufacturing. The company addresses the need for efficient and reliable manufacturing processes in the cell and gene therapy sector, ensuring that life-changing therapeutics reach patients effectively.

```xml <problem> The cell and gene therapy field faces challenges in scaling production from preclinical stages to commercial manufacturing, often encountering bottlenecks in efficient and reliable manufacturing processes. This can delay the delivery of potentially life-saving therapeutics to patients. </problem> <solution> OmniaBio is a contract development and manufacturing organization (CDMO) focused on cell and gene therapies, offering services from early process development through GMP commercial manufacturing. The company leverages advanced technologies, including AI and automation, within a Good Manufacturing Practices (GMP) environment to enhance cell and gene therapy production. OmniaBio specializes in platforms for induced pluripotent stem cells (iPSC), lentiviral vectors (LVV), and immune cell-based therapies. By integrating these platforms with comprehensive analytical development and regulatory support, OmniaBio aims to streamline the path to market for transformative treatments, ensuring scalability, cost-effectiveness, and regulatory compliance. </solution> <features> - Process development and optimization for cell and gene therapies, focusing on robustness and scale-up - Analytical development services for tailored and established assays - GMP manufacturing in Grade B or Grade C suites, compliant with U.S., Canadian, and European regulations - Commercial manufacturing with efficient scalability and timely QC release - Autologous cell therapy manufacturing integrating closed-unit systems, AI models, and robotics - Cell banking services - Regulatory guidance throughout the product lifecycle - Supply chain security measures </features> <target_audience> OmniaBio serves biotech companies, pharmaceutical firms, and research institutions involved in developing cell and gene therapies, from early-stage development to commercialization. </target_audience> ```

What does OmniaBio do?

OmniaBio is a contract development and manufacturing organization specializing in the production of gene-modified cell therapies and lentiviral vectors, facilitating the transition from preclinical development to commercial-scale manufacturing. The company addresses the need for efficient and reliable manufacturing processes in the cell and gene therapy sector, ensuring that life-changing therapeutics reach patients effectively.

Where is OmniaBio located?

OmniaBio is based in Hamilton, Canada.

When was OmniaBio founded?

OmniaBio was founded in 2022.

Location
Hamilton, Canada
Founded
2022
Employees
129 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

OmniaBio

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

OmniaBio is a contract development and manufacturing organization specializing in the production of gene-modified cell therapies and lentiviral vectors, facilitating the transition from preclinical development to commercial-scale manufacturing. The company addresses the need for efficient and reliable manufacturing processes in the cell and gene therapy sector, ensuring that life-changing therapeutics reach patients effectively.

omniabio.com10K+
Founded 2022Hamilton, Canada

Funding

No funding information available.

Team (100+)

No team information available.

Company Description

Problem

The cell and gene therapy field faces challenges in scaling production from preclinical stages to commercial manufacturing, often encountering bottlenecks in efficient and reliable manufacturing processes. This can delay the delivery of potentially life-saving therapeutics to patients.

Solution

OmniaBio is a contract development and manufacturing organization (CDMO) focused on cell and gene therapies, offering services from early process development through GMP commercial manufacturing. The company leverages advanced technologies, including AI and automation, within a Good Manufacturing Practices (GMP) environment to enhance cell and gene therapy production. OmniaBio specializes in platforms for induced pluripotent stem cells (iPSC), lentiviral vectors (LVV), and immune cell-based therapies. By integrating these platforms with comprehensive analytical development and regulatory support, OmniaBio aims to streamline the path to market for transformative treatments, ensuring scalability, cost-effectiveness, and regulatory compliance.

Features

Process development and optimization for cell and gene therapies, focusing on robustness and scale-up

Analytical development services for tailored and established assays

GMP manufacturing in Grade B or Grade C suites, compliant with U.S., Canadian, and European regulations

Commercial manufacturing with efficient scalability and timely QC release

Autologous cell therapy manufacturing integrating closed-unit systems, AI models, and robotics

Cell banking services

Regulatory guidance throughout the product lifecycle

Supply chain security measures

Target Audience

OmniaBio serves biotech companies, pharmaceutical firms, and research institutions involved in developing cell and gene therapies, from early-stage development to commercialization.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.